Metformin: From Diabetes Staple to Cancer Therapy Adjuvant

Est. Reading Time: 9 Minutes

Metformin is one of the most widely prescribed medications in the world, with more than 200 million people estimated to be taking it worldwide. Best known as a first-line treatment for type 2 diabetes, it’s inexpensive, generally well tolerated, and backed by decades of clinical experience. But over the last 20 years, this unassuming drug has quietly entered a different conversation: cancer therapy. What started as a curious observation in diabetic patients has grown into a serious area of oncology research, positioning metformin as one of the most promising examples of drug repurposing in modern medicine.

What is Metformin?

Metformin is an oral medication in the biguanide drug class and, as mentioned, has been a staple for type 2 diabetes treatment for decades. Clinically, it works by reducing glucose production in the liver, improving insulin sensitivity, and lowering circulating insulin levels; all without causing weight gain or hypoglycemia, which makes it unique among diabetes medications.

Chemically, metformin is a small, positively charged molecule (1,1-dimethylbiguanide) that readily accumulates in cells, particularly in mitochondria. This property turns out to be critically important when we start talking about cancer.

A Brief History: How and Why Metformin Was Developed

Metformin’s origins trace back to Galega officinalis, or goat’s rue, a traditional European herbal remedy known to contain guanidine (a compound shown to lower blood glucose in 1918). Several guanidine-derived drugs were created to treat diabetes in the 1920s and 30s but were subsequently abandoned due to toxicity concerns and the growing availability of insulin.

Metformin resurfaced in the 1940s during efforts to develop antimalarial agents, when clinicians noticed it could lower blood glucose during treatment. This observation was pursued by French physician Jean Sterne, who first formally reported the use of metformin in diabetes in 1957. At first, metformin received little attention compared to its more potent counterparts, Phenformin and buformin, but that exact characteristic allowed it to rise through the ranks. It had the same effects but without the toxicity.

After extensive evaluation, metformin was finally introduced in the United States in 1995.

The Accidental Discovery of Anticancer Effects

Metformin’s entry into oncology was not planned; it was noticed.

In the early 2000s, researchers observed something unexpected: diabetic patients taking metformin appeared to have lower rates of cancer incidence and cancer-related mortality compared to people with diabetes on other medications. These findings, first observed in extensive epidemiological studies, sparked widespread curiosity.

This wasn’t a single fluke observation. Multiple retrospective analyses across different populations and cancer types point in the same direction: metformin users were doing better.

How Might Metformin Fight Cancer?

Metabolism at the Center of the Story

Cancer cells are metabolically different from healthy cells. Many rely heavily on glucose and altered energy pathways to fuel rapid growth. Metformin directly interferes with this vulnerability.

At the cellular level, Metformin activates AMP-activated protein kinase (AMPK). This key energy sensor tells cells when fuel is low. When AMPK is activated, it suppresses growth-promoting pathways such as mTOR, effectively putting the brakes on cell proliferation.

Lower Insulin, Lower Growth Signals

Metformin also works indirectly. By lowering blood glucose and insulin levels, it reduces activation of insulin and IGF-1 signaling pathways, which are known to promote tumor growth and survival.

Synergy With Existing Treatments

It also appears to enhance the effectiveness of chemotherapy while also helping to reduce its toxicity. When combined with chemotherapy, metformin can improve tumor response by suppressing those pathways mentioned above, increasing cancer cell sensitivity to treatment, and overcoming chemotherapy resistance. Studies across multiple cancers, including ovarian, breast, leukemia, and lymphoma, suggest that metformin works best when given before or alongside chemotherapy, helping create a metabolic environment less favorable for tumor growth.

Metformin was also shown to enhance the effectiveness of immunotherapy by improving the immune system’s ability to recognize and attack cancer cells. While immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have transformed cancer treatment, only a minority of patients respond, and some tumors remain largely resistant. But, research suggests metformin can help overcome these limitations by reshaping the tumor microenvironment and immune cell metabolism.

What Cancers are Vulnerable to Metformin?

The strongest signals so far have appeared in:

  • Colorectal Cancer
  • Pancreatic Cancer
  • Liver Cancer

​
It has also shown promising results in studies against:

  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Glioma (Brain)
  • Melanoma
  • Endometrial Cancer

​
Large reviews and meta-analyses suggest improved outcomes in specific subgroups, particularly in metabolically driven cancer and in patients with insulin resistance.
​
That said, results have not been universally positive, stressing the importance of patient selection, dosing, combination strategies, and, of course, more clinical research.

Metformin in Clinical Trials

Completed and Published Trials

Metformin has been involved in over 200 clinical trials involving cancer as a neoadjuvant, adjuvant, and metastatic treatment, often in combination with chemotherapy, radiation, or targeted therapies. Some trials have shown improved progression-free survival or metabolic markers associated with better outcomes, while others have demonstrated neutral effects.

Completed Clinical Trials Involving Metformin for Cancer.

Importantly, neutral results do not necessarily mean failure. Many studies suggest that metformin’s benefit may be context-dependent, influenced by tumor type, metabolic status, and treatment timing.

Ongoing and New Clinical Trials

Interest in metformin has not slowed; there are currently dozens of recruiting and active clinical trials exploring metformin in cancer treatment, including combinations with immunotherapy and metabolic intervention.

Current Clinical Trials Involving Metformin for Cancer.

Who Is Using Metformin in Cancer Care Today?

Metformin is not FDA-approved as a cancer treatment. However, it is still prescribed off-label by oncologists and integrative oncology practitioners, particularly for patients suffering from insulin resistance, metabolic syndrome, or diabetes.
​
Despite the evidence, metformin is underutilized in oncology, with one of the main barriers being limited pharmaceutical incentives to fund large trials for an inexpensive generic drug.

Safety and Practical Considerations

Metformin’s safety profile is one of its greatest strengths. Common side effects are gastrointestinal and often transient. Rare risks include vitamin B12 deficiency and lactic acidosis in patients with advanced kidney disease.
​
These characteristics make metformin especially attractive as a long-term adjunct therapy.

Looking Ahead: The Future of Metformin in Oncology

Metformin’s story is far from over. Ongoing research is exploring:

  • Biomarkers to predict response
  • Synergy with immunotherapy
  • Metabolic phenotyping to personalize treatment

​
As our understanding of cancer metabolism deepens, metformin may find its most powerful role not as a standalone therapy, but as part of a metabolically informed, combination-based approach to cancer care.

Final Thoughts

Metformin represents a fascinating intersection of metabolism, oncology, and drug repurposing. It challenges the idea that effective cancer therapies must be novel, expensive, or highly toxic. Instead, it suggests that sometimes, the most powerful tools are already in our medicine cabinets, waiting for us to ask the right questions.

Sources


  1. https://www.uchealth.org/today/truth-about-metformin-is-it-a-wonder-drug/
  2. https://www.ncbi.nlm.nih.gov/books/NBK518983/
  3. https://pubmed.ncbi.nlm.nih.gov/28776081/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4160009/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC5772929/
  6. https://www.sciencedirect.com/science/article/pii/S193652332400072X
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC10286395/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5130043/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC12471648/
  10. https://cancerchoices.org/therapy/metformin/expert-use/
  11. https://www.mayoclinic.org/drugs-supplements/metformin-oral-route/description/drg-20067074

Related Categories: Research Article

Disclaimer: This article is for educational purposes only and is not medical advice. Always consult your clinician before making any medical or medication decisions.